- Practice your CELG trading strategies and win cash in our stock game.
NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Monday as it is currently trading at $66.37, above its previous 52-week high of $65.86 with 893,213 shares traded as of 10:10 a.m. ET. Average volume has been four million shares over the past 30 days. Celgene has a market cap of $29.4 billion and is part of the health care sector and drugs industry. Shares are up 8.4% year to date as of the close of trading on Friday. Celgene Corporation, an integrated biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. The company has a P/E ratio of 29.3, below the average drugs industry P/E ratio of 29.5 and above the S&P 500 P/E ratio of 17.7.